News

The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12…

Scientists have discovered a new regulator — called NHR-49 — that may shed light and open potential new therapeutic avenues to prevent the formation of toxic protein clumps, a hallmark of aging-related diseases, including Parkinson’s disease. Using embryos of the roundworm Caenorhabditis elegans, they found that NHR-49 is activated…

Anew Medical said it will advance clinical development of its Klotho gene therapy program to prevent or stop the progression of neurodegenerative diseases, including Parkinson’s disease. Initial data suggest that maintaining high levels of the Klotho protein in the body may help people live longer and healthier…

Combining gait training with virtual reality and gamification elements — when game-like features are added to non-game activities — may help people with Parkinson’s disease see rehabilitation as a positive experience, a study suggests. That, in turn, could ultimately lead to better motor outcomes for patients, according to researchers.

People with a genetic predisposition to Parkinson’s disease are more likely to have early-onset symptoms, but lifestyle factors such as coffee consumption and tobacco and aspirin use may exert a more significant impact on that risk than common genetic risks, research findings suggest. While still exploratory, “our findings underline…

Mission Therapeutics has received $5.2 million from The Michael J. Fox Foundation (MJFF) and Parkinson’s UK to start clinical testing MTX325, its experimental and neuron-protective oral therapy, in people in the early stages of Parkinson’s disease. “This significant grant, from two of the world’s leading Parkinson’s disease…

Clumps of RNA-binding proteins have been discovered in the nucleus of nerve cells derived from people with Parkinson’s disease, according to a new study. Generated by a “self-propagating” cycle, these clumps were different and separate from those made from the protein alpha-synuclein, a well-known feature of Parkinson’s. A second…

Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinson’s disease, and improved cognition in those with mild dementia. That’s according to new data from a Phase 3 trial (NCT05357989), which showed that the therapy candidate, developed by Annovis Bio,…

Two proteins, Aplp1 and Lag3, pair to allow toxic aggregates of alpha-synuclein — a hallmark of Parkinson’s disease — into nerve cells and help it spread across the brain, according to a study in mice. “Now that we know how Aplp1 and Lag3 interact, we have a new way…

BrainTale’s noninvasive imaging analysis software, BrainTale-care, may be able to distinguish Parkinson’s disease from atypical parkinsonism. That’s according to data from an advanced MRI technique, called diffusion tensor imaging, that measures the diffusion of water molecules in the brain’s white matter. White matter contains nerve fibers…